Warts (verruca vulgaris) is the most common form of viral wart. Caused by the papillomavirus (HPV), three out of four people will develop this type of wart at some point in their lives.

The goal of the clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with ...

We describe a complication of Candida albicans (CA) antigen treatment of verruca vulgaris in the subungual area of the distal fingertip. 1 2 3. Next Section. Dermatitis. 2005;16(1) ...

Vial has entered a partnership with Nielsen BioSciences Inc. to support Nielsen’s phase 3 trial of Candin for the treatment of verruca vulgaris, according to a company press release.This ...

SAN DIEGO, February 26, 2025--Nielsen BioSciences announced the final patient has been successfully enrolled in the CFW-3A trial for CANDIN in common warts.

The goal of the clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with ...